Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945756507> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2945756507 abstract "Background Olaparib and Niraparib are oral antineoplastics used for the maintenance treatment of high-grade ovarian cancer, relapsed, complete or partial response to platinum-based chemotherapy. Olaparib is indicated for patients with BRCA +mutation and marketed in our country: Niraparib is independent of the mutation and it is used in compassionate use. Purpose Comparing the safety profile of Niraparib and Olaparib, in the everyday clinical practice of a tertiary hospital. Material and methods Descriptive, transversal, retrospective research of all patients treated with Niraparib or Olaparib until September 2018. Data: clinical and pharmacological history (Farmatools). Variables: age, date of beginning, end and/or reintroduction of treatment, reason for suspension, initial dose, dose reduction, current dose, days of treatment and adverse effects. Analysis: SPSS Statistics. Results Eight patients with Olaparib and 11 with Niraparib, with an average age of 65 (50–86) and 61 (48–73) respectively. The median of treatment with Olaparib was 455 (25–1264) and with Niraparib 35 (2–91). Olaparib: seven (87.5%) patients started with 400 mg and one (12.5%) with 200 mg. Three (50%) needed dose reduction and all had started with 400 mg. In two patients the treatment was suspended due to death and progression respectively. Six (75%) continued in treatment (three with 400 mg, two 200 mg and one 100 mg). In one (16.7%) of them the treatment was temporarily suspended due to decreased haemoglobin and three (37.5%) had adverse effects (nausea, vomiting, stomach pain) without interruption of treatment. Niraparib: four (36.4%) patients started with 300 mg and seven (63.6%) 200 mg. Five (45.5%) patients needed dose reduction, two with initial dose 300 mg and three 200 mg: three of them continued (one of 300 mg and two of 200 mg initial dose). In five (45.5%) patients, treatment was discontinued, two (40%) due to adverse effects (neutropaenia, thrombocytopaenia and increased creatinine respectively) and three due to progression (60%), in addition temporarily suspending it due to neutropaenia. Six continued (three with 200 mg and three with 100 mg) and three of them had to temporarily interrupt it due to thrombocytopaenia. Conclusion In both treatments, the haematological adverse effects are more severe, frequent and worse tolerated in the case of Niraparib than Olaparib. In addition, greater discontinuity of treatment is observed in patients with Niraparib. References and/or acknowledgements No conflict of interest." @default.
- W2945756507 created "2019-05-29" @default.
- W2945756507 creator A5010954841 @default.
- W2945756507 creator A5012873414 @default.
- W2945756507 creator A5063976827 @default.
- W2945756507 creator A5066175242 @default.
- W2945756507 creator A5068431648 @default.
- W2945756507 creator A5069593505 @default.
- W2945756507 creator A5073931614 @default.
- W2945756507 creator A5077426799 @default.
- W2945756507 date "2019-03-01" @default.
- W2945756507 modified "2023-09-27" @default.
- W2945756507 title "5PSQ-057 Olaparib and niraparib safety profile in the clinical practice of a tertiary-level hospital" @default.
- W2945756507 doi "https://doi.org/10.1136/ejhpharm-2019-eahpconf.490" @default.
- W2945756507 hasPublicationYear "2019" @default.
- W2945756507 type Work @default.
- W2945756507 sameAs 2945756507 @default.
- W2945756507 citedByCount "1" @default.
- W2945756507 countsByYear W29457565072019 @default.
- W2945756507 crossrefType "proceedings-article" @default.
- W2945756507 hasAuthorship W2945756507A5010954841 @default.
- W2945756507 hasAuthorship W2945756507A5012873414 @default.
- W2945756507 hasAuthorship W2945756507A5063976827 @default.
- W2945756507 hasAuthorship W2945756507A5066175242 @default.
- W2945756507 hasAuthorship W2945756507A5068431648 @default.
- W2945756507 hasAuthorship W2945756507A5069593505 @default.
- W2945756507 hasAuthorship W2945756507A5073931614 @default.
- W2945756507 hasAuthorship W2945756507A5077426799 @default.
- W2945756507 hasBestOaLocation W29457565071 @default.
- W2945756507 hasConcept C104317684 @default.
- W2945756507 hasConcept C121608353 @default.
- W2945756507 hasConcept C126322002 @default.
- W2945756507 hasConcept C143998085 @default.
- W2945756507 hasConcept C182979987 @default.
- W2945756507 hasConcept C185592680 @default.
- W2945756507 hasConcept C197934379 @default.
- W2945756507 hasConcept C2776694085 @default.
- W2945756507 hasConcept C2779962180 @default.
- W2945756507 hasConcept C2780194787 @default.
- W2945756507 hasConcept C2780427987 @default.
- W2945756507 hasConcept C2780580376 @default.
- W2945756507 hasConcept C2780852908 @default.
- W2945756507 hasConcept C29456083 @default.
- W2945756507 hasConcept C55493867 @default.
- W2945756507 hasConcept C71924100 @default.
- W2945756507 hasConcept C82381507 @default.
- W2945756507 hasConceptScore W2945756507C104317684 @default.
- W2945756507 hasConceptScore W2945756507C121608353 @default.
- W2945756507 hasConceptScore W2945756507C126322002 @default.
- W2945756507 hasConceptScore W2945756507C143998085 @default.
- W2945756507 hasConceptScore W2945756507C182979987 @default.
- W2945756507 hasConceptScore W2945756507C185592680 @default.
- W2945756507 hasConceptScore W2945756507C197934379 @default.
- W2945756507 hasConceptScore W2945756507C2776694085 @default.
- W2945756507 hasConceptScore W2945756507C2779962180 @default.
- W2945756507 hasConceptScore W2945756507C2780194787 @default.
- W2945756507 hasConceptScore W2945756507C2780427987 @default.
- W2945756507 hasConceptScore W2945756507C2780580376 @default.
- W2945756507 hasConceptScore W2945756507C2780852908 @default.
- W2945756507 hasConceptScore W2945756507C29456083 @default.
- W2945756507 hasConceptScore W2945756507C55493867 @default.
- W2945756507 hasConceptScore W2945756507C71924100 @default.
- W2945756507 hasConceptScore W2945756507C82381507 @default.
- W2945756507 hasLocation W29457565071 @default.
- W2945756507 hasOpenAccess W2945756507 @default.
- W2945756507 hasPrimaryLocation W29457565071 @default.
- W2945756507 hasRelatedWork W1537122182 @default.
- W2945756507 hasRelatedWork W2022077452 @default.
- W2945756507 hasRelatedWork W2147057518 @default.
- W2945756507 hasRelatedWork W2352498912 @default.
- W2945756507 hasRelatedWork W2367325605 @default.
- W2945756507 hasRelatedWork W2369852829 @default.
- W2945756507 hasRelatedWork W2386145890 @default.
- W2945756507 hasRelatedWork W3030704001 @default.
- W2945756507 hasRelatedWork W3031554156 @default.
- W2945756507 hasRelatedWork W4214702985 @default.
- W2945756507 isParatext "false" @default.
- W2945756507 isRetracted "false" @default.
- W2945756507 magId "2945756507" @default.
- W2945756507 workType "article" @default.